Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04171141
Recruitment Status : Recruiting
First Posted : November 20, 2019
Last Update Posted : October 14, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
A phase 1, open-label, dose escalation and expansion study of PF-07062119 in patients with selected advanced or metastatic gastrointestinal tumors

Condition or disease Intervention/treatment Phase
Gastrointestinal Tumors Colorectal Adenocarcinomas Gastric Adenocarcinomas Esophageal Adenocarcinomas Drug: PF-07062119 Drug: Anti-PD1 Drug: Anti-VEGF Phase 1

Detailed Description:
This is a Phase 1, open-label, multi-center, non-randomized, multiple dose, safety, tolerability, pharmacokinetic, and pharmacodynamic study of PF-07062119 administered as a single agent in sequential dose levels and then in combination with anti-programmed cell death -1 protein (anti-PD-1) and in combination with an anti-vascular endothelial growth factor (anti-VEGF). In Part 1A, successive cohorts of patients will receive escalating doses of PF-007062119 and then in dose finding (Part 1B) with PF-07062119 in combination with anti-PD-1 and in combination with anti-VEGF. This study contains 2 parts, dose escalation with single agent (Part 1A) and then dose finding with PF-007062119 in combination with ant-PD-1 and in combination with anti-VEGF (Part 1B) followed by dose expansion arms as a single agent and PF-07062119 in combination with anti-PD 1 and in combination with anti-VEGF (Part 2).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 110 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS AND ANTI TUMOR ACTIVITY OF PF-07062119 IN PATIENTS WITH ADVANCED GASTROINTESTINAL TUMORS
Actual Study Start Date : November 19, 2019
Estimated Primary Completion Date : October 17, 2022
Estimated Study Completion Date : October 17, 2022

Resource links provided by the National Library of Medicine

Drug Information available for: Bevacizumab

Arm Intervention/treatment
Experimental: Dose Escalation
Single Agent Dose Escalation
Drug: PF-07062119
PF-07062119

Experimental: Dose Finding Anti-PD-1 Combination
Part 1B PF-07062119 plus anti-PD-1
Drug: PF-07062119
PF-07062119

Drug: Anti-PD1
Anti-PD1 PF-06801591

Experimental: Dose Finding anti-VEGF Combination
Part 1B PF-07062119 plus anti-VEGF
Drug: PF-07062119
PF-07062119

Drug: Anti-VEGF
Anti-VEGF IV (bevacizumab)

Experimental: Dose Expansion Arm A
PF-07062119 as a Single Agent in CRC
Drug: PF-07062119
PF-07062119

Experimental: Dose Expansion Arm B
PF-07062119 in Combination with anti-PD-1 in CRC
Drug: PF-07062119
PF-07062119

Experimental: Dose Expansion Arm C
PF-07062119 in Combination with anti-VEGF in CRC
Drug: PF-07062119
PF-07062119

Drug: Anti-PD1
Anti-PD1 PF-06801591

Drug: Anti-VEGF
Anti-VEGF IV (bevacizumab)

Experimental: Dose Expansion Arm D
PF-07062119 in Combination with either anti-PD-1 or anti-VEGF in various Tumor Types
Drug: PF-07062119
PF-07062119

Drug: Anti-PD1
Anti-PD1 PF-06801591

Drug: Anti-VEGF
Anti-VEGF IV (bevacizumab)




Primary Outcome Measures :
  1. Number of participants with Dose-limiting toxicities (DLT) in Cycle 1 [ Time Frame: Baseline up to 28 days ]
  2. Number of Participants With Clinically Significant Change From Baseline in Laboratory Abnormalities [ Time Frame: Baseline up to approximately 24 months ]
  3. Duration of Adverse Events (AEs) [ Time Frame: Baseline up to approximately 24 months ]
  4. Number of Participants With Adverse Events (AEs) According to Severity [ Time Frame: Baseline up to approximately 24 months ]
  5. Number of Participants With Adverse Events (AEs) According to Seriousness [ Time Frame: Baseline up to up to approximately 24 months ]
  6. Number of Participants With Adverse Events (AEs) by Relationship [ Time Frame: Baseline up to approximately 24 months ]
  7. Objective Response - Number of Participants With Objective Response for Dose Expansion (Part 2) [ Time Frame: Baseline (1st dosing) up to approximately 24 months ]

Secondary Outcome Measures :
  1. Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  2. Incidence of Anti-Drug Antibody (ADA) an Neutralizing Antibodies (Nab) for PF-07062119 [ Time Frame: Up to approximately 24 months ]
  3. Incidence of Anti-Drug Antibody (ADA) an Neutralizing Antibodies anti-PD1 [ Time Frame: Up to approximately 24 months ]
  4. Incidence of Anti-Drug Antibody (ADA) an Neutralizing Antibodies (Nab) for anti-VEGF [ Time Frame: Up to approximately 24 months ]
  5. Apparent Clearance (CL/F) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  6. Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  7. Maximum Observed Plasma Concentration (Cmax) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  8. Time to Reach Maximum Observed Plasma Concentration (Tmax) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  9. Terminal Half-Life (t1/2) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  10. Objective Response - Number of Participants With Objective Response for Dose Escalation [ Time Frame: Baseline up to 24 months ]
  11. Objective Response - Number of Participants With Objective Response for Dose Finding portion [ Time Frame: Baseline up to 24 months ]
  12. Minimum Observed Plasma Trough Concentration (Cmin) [ Time Frame: Cycle 1 (each cycle is 28 days) and Day 1 of each subsequent cycle and at study completion visit, up to approximately 24 months ]
  13. Progression-Free Survival (PFS) for Dose Expansion [ Time Frame: Baseline to measured progressive disease (up to 24 months) ]
  14. Duration of Response (DR) for Dose Expansion [ Time Frame: Baseline up to approximately 24 months ]
  15. Change from baseline of immune cells from tumor biopsies [ Time Frame: Baseline and Cycle 2, Day 1 (each cycle is 28 days) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • For Part 1 and Part 2, diagnosis of advanced/metastatic colorectal, gastric or esophageal adenocarcinoma that is resistant to standard therapy or for which no local regulatory approved standard therapy is available that would confer significant benefit.
  • For Part 2, diagnosis of colorectal adenocarcinoma that is resistant to standard therapy or for which no standard therapy is available
  • Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
  • Measurable disease or non-measurable disease and refractory to or intolerant of existing therapies (Part 1)
  • Measurable disease as defined by RECIST 1.1 is required (Part 2)

Exclusion Criteria:

  • Known active uncontrolled or symptomatic Central Nervous System (CNS) metastases
  • Other active malignancy within 3 years prior to randomization, except for adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ
  • Major surgery or radiation within 3 weeks prior to study entry
  • Last anti-cancer treatment within 4 weeks prior to study entry
  • Active or history of clinically significant autoimmune disease that required systemic immunosuppressive medication
  • Active or history of clinically significant gastrointestinal disease
  • Participation in other studies involving investigational drug(s) within 2 weeks prior to study entry
  • Pregnant or breastfeeding female patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04171141


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Locations
Layout table for location information
United States, California
City of Hope (City of Hope National Medical Center, City of Hope Medical Center) Recruiting
Duarte, California, United States, 91010
City of Hope IDS Pharmacy Recruiting
Duarte, California, United States, 91010
United States, Colorado
Anschutz Cancer Pavilion Not yet recruiting
Aurora, Colorado, United States, 80045
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP) Not yet recruiting
Aurora, Colorado, United States, 80045
University of Colorado Hospital - Anschutz Inpatient Pavilion (AIP) Not yet recruiting
Aurora, Colorado, United States, 80045
University of Colorado Hospital - Anschutz Outpatient Pavilion (AOP) Not yet recruiting
Aurora, Colorado, United States, 80045
United States, New York
Memorial Sloan Kettering Cancer Center Rockefeller Outpatient Pavillion Recruiting
New York, New York, United States, 10022
Memorial Sloan Kettering Cancer Center - Main Campus Recruiting
New York, New York, United States, 10065
United States, Texas
University of Texas MD Anderson Cancer Center Recruiting
Houston, Texas, United States, 77030
Christus Santa Rosa Hospital Recruiting
San Antonio, Texas, United States, 78229
NEXT Oncology Recruiting
San Antonio, Texas, United States, 78229
Japan
National Cancer Center Hospital East Recruiting
Kashiwa, Chiba, Japan, 277-8577
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT04171141    
Other Study ID Numbers: C3861001
GUCY2C ( Other Identifier: Alias Study Number )
First Posted: November 20, 2019    Key Record Dates
Last Update Posted: October 14, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
Gastric cancer
Esophageal cancer
Colorectal cancer
Advanced esophageal cancer
Metastatic esophageal cancer
Advanced colorectal cancer
Metastatic gastric cancer
Advanced gastric cancer
Metastatic colorectal cancer
GUCY2c
Anti-PD1
Anti-VEGF
Measurable disease
PF-07062119
PF-06801591
Bevacizumab
Additional relevant MeSH terms:
Layout table for MeSH terms
Adenocarcinoma
Digestive System Neoplasms
Gastrointestinal Neoplasms
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Bevacizumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors